 Home > Active Ingredient News > Blood System > J Clin Oncol: Donor-derived CD7 chimeric antigen receptor T cells for the treatment of acute T lymphocytic leukemia can be expected in the future!

J Clin Oncol: Donor-derived CD7 chimeric antigen receptor T cells for the treatment of acute T lymphocytic leukemia can be expected in the future!

 Last Update: 2021-08-04
 Source: Internet
 Author: User

Tags

mononuclear cells

hybrid battery cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Acute T-lymphocytic leukemia (T-ALL) is an aggressive hematological malignancy that accounts for 10%-15% of childhood acute lymphoblastic leukemia (ALL) cases and 20% of adult ALL cases
.

Patients with relapsed or refractory T-ALL (r/r T-ALL) have few treatment options and poor prognosis

child

The purpose of this study is to evaluate the efficacy and safety of patient-derived anti-CD7 chimeric antigen receptor (CAR) T cells used in r/r T-ALL patients
.

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

This is a single-center phase 1 trial in which CD7 CAR T cells were infused into r/r T-ALL patients at a dose of 5×10 ⁵ /kg or 1×10 ⁶ /kg (±30%)
.

The primary endpoint is safety, and the secondary endpoint is efficacy

⁵⁶

A total of 20 patients received CAR T cell infusion
.

Adverse events include cytokine release syndrome (grade 1-2: 90%; grade 3-4: 10%), grade 3-4 cytopenia (100%), grade 1-2 neurotoxicity (15%) ), grade 1-2 graft versus host disease (60%), and grade 1-2 virus activation (20%)

Clinical remission

Ninety percent of patients achieved complete remission, and 7 patients underwent stem cell transplantation
.

At a median follow-up of 6.

Ninety percent of patients achieved complete remission, and 7 patients underwent stem cell transplantation

immunity

In summary, among the 20 r/r T-ALL patients who participated in the trial, the donor-derived CD7 CAR T cells showed effective expansion, and achieved a high complete remission rate and controllable safety.
Sex
.

Donor-derived CD7 CAR T cells showed effective expansion and achieved a high complete remission rate and controllable safety
.

Donor-derived CD7 CAR T cells showed effective expansion and achieved a high complete remission rate and controllable safety

Original source:

Jing Pan, et al.

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.